In Vivo Characterization of Rabbit Anti-Mouse Thymocyte Globulin: A Surrogate for Rabbit Anti-Human Thymocyte Globulin
- 27 July 2009
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Transplantation
- Vol. 88 (2), 170-179
- https://doi.org/10.1097/tp.0b013e3181abc061
Abstract
Background. Polyclonal rabbit anti-human thymocyte globulin (Thymoglobulin) is used clinically for immunosuppression in solid organ transplantation; however, it is difficult to fully characterize the effects of this agent in humans. Methods. A surrogate rabbit anti-murine thymocyte globulin (mATG) was generated analogously to the commercial product Thymoglobulin and in vivo activities were evaluated, including pharmacokinetics, T-cell depletion, dose response and kinetics, depletion/sparing of T-cell subsets or other leukocyte populations, and depletion in different lymphoid organs. Results. Within 1 day, T cells are depleted by mATG in the blood, spleen, lymph node, and bone marrow down to doses of 1 mg/kg. Although mATG binds and depletes thymocytes in vitro, there is no thymocyte depletion in vivo at any dose level, suggesting decreased antibody accessibility to the thymus. After two doses of mATG given 3 days apart, T-cell reconstitution begins as early as day 9 and returns to basal levels by day 21 and 29 for CD4 and CD8 T cells, respectively. There is also preferential depletion of naïve T cells that results in increased ratios of regulatory and memory T cells within 1 day after mATG administration. Depletion of natural killer-T cells, natural killer cells, plasma cells, and plasmablasts occurs, but is modest and more transient compared with T cells. B cells, macrophages, dendritic cells, hematopoetic stem cells, and bone marrow stromal cells seem resistant to mATG depletion. Conclusions. These studies characterize the depletive effects of mATG in normal mice and provide insight into mechanisms of action of Thymoglobulin.Keywords
This publication has 42 references indexed in Scilit:
- Simultaneous Protection Against Allograft Rejection and Graft-Versus-Host Disease After Total Lymphoid Irradiation: Role of Natural Killer T CellsTransplantation, 2008
- Effector memory CD4+ T cells mediate graft-versus-leukemia without inducing graft-versus-host diseaseBlood, 2008
- Serotherapy with thymoglobulin and alemtuzumab differentially influences frequency and function of natural killer cells after allogeneic stem cell transplantationBone Marrow Transplantation, 2007
- Short administration of polyclonal anti-T cell antibody (ALS) in NOD mice with extensive insulitis prevents subsequent development of autoimmune diabetesJournal of Autoimmunity, 2006
- Heterogeneous Clearance of Antithymocyte Globulin after CD34+-Selected Allogeneic Hematopoietic Progenitor Cell TransplantationTransplantation and Cellular Therapy, 2005
- Antilymphocyte/thymocyte globulin for graft versus host disease prophylaxis: efficacy and side effectsBone Marrow Transplantation, 2004
- Total and active thymoglobulin levels: effects of dose and sensitization on serum concentrationsTransplant Immunology, 2001
- Persistent Long-Term Changes In Lymphocyte Subsets Induced By Polyclonal Antibodies1Transplantation, 1997
- COMPARATIVE POLYCLONAL ANTITHYMOCYTE GLOBULIN AND ANTILYMPHOCYTE/ANTILYMPHOBLAST GLOBULIN ANTI-CD ANTIGEN ANALYSIS BY FLOW CYTOMETRYTransplantation, 1995
- In Vivo use of monoclonal antibodies against murine T cell antigensClinical Immunology and Immunopathology, 1989